The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications
Open accessAbstract
The incidence of nonalcoholic fatty liver disease (NAFLD) is increasing recently and has become one of the most common clinical liver diseases. Since the pathogenesis of NAFLD has not been completely elucidated, few effective therapeutic drugs are available. As the “second genome” of human body, gut microbiota plays an important role in the digestion, absorption and metabolism of food and drugs. Gut microbiota can act as an important driver to advance the occurrence and development of NAFLD, and to accelerate its progression to cirrhosis and hepatocellular carcinoma. Growing evidence has demonstrated that gut microbiota and its metabolites directly affect intestinal morphology and immune response, resulting in the abnormal activation of inflammation and intestinal endotoxemia; gut dysbiosis also causes dysfunction of gut-liver axis via alteration of bile acid metabolism pathway. Because of its composition diversity and disease-specific expression characteristics, gut microbiota holds strong promise as novel biomarkers and therapeutic targets for NAFLD. Intervening intestinal microbiota, such as antibiotic/probiotic treatment and fecal transplantation, has been a novel strategy for preventing and treating NAFLD. In this article, we have reviewed the emerging functions and association of gut bacterial components in different stages of NAFLD progression and discussed its potential implications in NAFLD diagnosis and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781 · cited 7×
“These results suggest that the regulation of gut microbiota may be a new target for NAFLD-related HCC and cirrhosis therapy.”
BackgroundInfluentialFecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757
Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science · doi:10.1126/science.aan5931 · Cited by 1,508
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931 · cited 1×
“Short-term oral administration of OCA improved insulin resistance and reduced markers of liver fibrosis in patients with NASH combined with type 2 diabetes (Mudaliar et al., 2013; Pockros et al., 2019).”
BackgroundJiao, N., Baker, S. S., Chapa-Rodriguez, A., Liu, W., Nugent, C. A., Tsompana, M., Mastrandrea, L., Buck, M. J., Baker, R. D., Genco, R. J., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314307 · Cited by 737 · cited 8×
“” Escherichia, Bilophila and Rhodobacter involved in BAs-mediating taurine and glycine metabolism were significantly increased in the faeces of NASH patients (Jiao et al., 2018).”
BackgroundInfluentialDel Chierico, F., Nobili, V., Vernocchi, P., Russo, A., De Stefanis, C., Gnani, D., Furlanello, C., Zandonà, A., Paci, P., Capuani, G., et al. (2017) · Hepatology · doi:10.1002/hep.28572 · Cited by 696
Mouries, J., Brescia, P., Silvestri, A., Spadoni, I., Sorribas, M., Wiest, R., Mileti, E., Galbiati, M., Invernizzi, P., Adorini, L., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.005 · Cited by 688
Lu, Y., Fan, C., Li, P., Lu, Y., Chang, X., & Qi, K. (2016) · Scientific Reports · doi:10.1038/srep37589 · Cited by 638
Cited by
Gut liver brain axis in diseases: the implications for therapeutic interventions
Yan, M., Man, S., Sun, B., Ma, L., Guo, L., Huang, L., & Gao, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01673-4 · Cited by 287
Benedé-Ubieto, R., Cubero, F. J., & Nevzorova, Y. A. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2331460 · Cited by 242
“8,110,111 Hence, these facts could induce an increase in gut permeability, triggering the activation of TLRs family and its consequent inflammation by LPS and endotoxin among other bacterial subproducts.”
BackgroundJourney of the Probiotic Bacteria: Survival of the Fittest
Mendonça, A. A., Pinto-Neto, W. D. P., da Paixão, G. A., Santos, D. D. S., De Morais, M. A., & De Souza, R. B. (2022) · Microorganisms · doi:10.3390/microorganisms11010095 · Cited by 82
Amini-Salehi, E., Hassanipour, S., Keivanlou, M.-H., Shahdkar, M., Orang Goorabzarmakhi, M., Vakilpour, A., Joukar, F., Hashemi, M., Sattari, N., Javid, M., et al. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuad086 · Cited by 42
Buchynskyi, M., Kamyshna, I., Halabitska, I., Petakh, P., Kunduzova, O., Oksenych, V., & Kamyshnyi, O. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1577724 · Cited by 30
Metadata
- Authors
- Fang, J., Yu, C.-H., Li, X.-J., Yao, J.-M., Fang, Z.-Y., Yoon, S.-H., & Yu, W.-Y.
- Venue
- Frontiers in Cellular and Infection Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2022-11-08
- Volume
- 12
- Pages
- 997018-997018
- ISSN
- 2235-2988 (ISSN-L)
- OpenAlex
- W4308592544
- Cited by
- 209
- References
- 24
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. https://app.cochat.ai/papers/10.3389/fcimb.2022.997018
- The paper
- Fang, J., Yu, C.-H., Li, X.-J., Yao, J.-M., Fang, Z.-Y., Yoon, S.-H., & Yu, W.-Y. (2022). Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2022.997018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.